Skip to main content

Table 1 Baseline participant characteristics of the intention-to-treat population (n = 206)

From: Clinical and cost effectiveness of arthritis gloves in rheumatoid arthritis (A-GLOVES): randomised controlled trial with economic analysis

 

Control (n = 103)

Intervention (n = 103)

Age (years): median (IQR)

60 (51,68)

58 (51,67)

Sex: female (%)

82 (80%)

84 (82%)

Diagnosis:

 RA

89 (86%)

87 (84%)

 UIA

14 (14%)

16 (16%)

Hand dominance:

 Right (%)

92 (89%)

93 (90%)

 Left (%)

9 (9%)

3 (3%)

 Both (%)

2 (2%)

7 (7%)

Living status: Alone (%)

18 (17%)

19 (18%)

Living with children: yes (%)

10 (10%)

14 (14%)

Employment status:

 Retired

50 (49%)

44 (43%)

  Due to ill health

9 (9%)

18 (17%)

  Other

41 (40%)

26 (25%)

 Full-time work

24 (24%)

21 (20%)

 Part-time work

13 (13%)

18 (17%)

 Homemaker

9 (9%)

6 (6%)

 Long-term sick

2 (2%)

7 (7%)

 Unemployed

3 (3%)

3 (3%)

 Self-employed

1 (1%)

3 (3%)

 Student

0 (0%)

1 (1%)

 Missing

1. (1%)

 

Symptom duration (months):

 Median (IQR)

60 (24,168)

72 (18,174)

Diagnosis duration (months):

 Median (IQR)

48 (10,144)

51 (8,168)

Medication regimen:

 0 DMARDs a

10

11

 1 DMARD

51

56

 2 or more DMARDs

42

36

 Biologics b

15

18

Started new/ changed DMARD or biologic in previous 3 months c: yes (%)

34 (33%)

34 (33%)

  1. aDMARD Disease Modifying Anti-Rheumatic Drug; bparticipants were also prescribed a DMARD; cstratification variable